Pharmanutra SpA (PHN.MI) stock: key figures, P/E, revenue and dividend
Consumer Staples · Italy · ISIN IT0005274094
Pharmanutra SpA financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 116.00 m EUR | 132.00 m EUR |
| Gross profit | 90.00 m EUR | 102.00 m EUR |
| EBIT | 28.00 m EUR | 30.00 m EUR |
| Net income | 16.00 m EUR | 20.00 m EUR |
| Diluted EPS – continuing operations | 1.67 EUR | 2.09 EUR |
Full history since 2015, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Pharmanutra SpA
Pharmanutra S.p.A., a nutraceutical company, engages in the research and development and marketing of food supplements and medical devices in Europe, the Middle East, Far East, North America, South America, and internationally. The company produces and distributes raw materials and active ingredients for the food, pharmaceutical, and dietary supplement industries. It offers Sucrosomial, a delivery system that optimises nutrient transport and absorption for minimising gastrointestinal side effects; and Cetylated Fatty Acids, a formulation for muscle and joint recovery in physiotherapy and sports. The company also sells instrumentation and software for body bioimpedance analysis through agents, distributors, and online sales. Pharmanutra S.p.A. was founded in 2000 and is headquartered in Pisa, Italy.
More stocks
- Logan Group Co Ltd (3380.HK)
- Jiangsu Jibeier Pharmaceutical Co Ltd (688566.SS)
- Iress Ltd (IRE.AX)
- Standard Foods Corp (1227.TW)
- SK IE Technology Co Ltd (361610.KS)
- Zhejiang Jihua Group Co Ltd (603980.SS)
- Cheng Loong Corp (1904.TW)
- Chongqing Constr Engineering (600939.SS)
- QITIAN Technology Group Co Ltd (300061.SZ)
- Pexip Holding ASA (PEXIP.OL)
- NICE Information Service Co. Ltd (030190.KS)
- Arteris, Inc. (AIP)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.